Ratings Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Real-time Estimate Cboe BZX Other stock markets 02:30:46 2024-05-28 pm EDT			5-day change	1st Jan Change
1.855 ^USD	-0.80%		+1.91%	-80.99%

May. 15	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	MT
May. 15	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
The company's share price in relation to its net book value makes it look relatively cheap.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-80.94%	509M	C
THERMO FISHER SCIENTIFIC	+10.03%	223B	B
DANAHER CORPORATION	+13.59%	195B	B-
INTUITIVE SURGICAL, INC.	+20.01%	144B	B-
BOSTON SCIENTIFIC CORPORATION	+30.83%	111B	A-
SIEMENS HEALTHINEERS AG	+2.17%	65.19B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.38%	53.02B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.64%	50.28B	B+
AGILENT TECHNOLOGIES, INC.	+8.37%	44.15B	A
GE HEALTHCARE TECHNOLOGIES INC.	+3.27%	36.45B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes